Buspirone — $0 on Listed Strengths
Buspirone is $0 on listed strengths only. Other strengths are not a blanket $0.
Buspirone Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 on listed strengths |
| Typical Retail | $69.99 |
$0 on listed strengths: 10mg Tablets (max 270); 15 mg Tablets (max 180); 30mg Tablets (max 180); 5mg Tablets (max 270); 7.5mg Tablets (max 270)
About Buspirone
Buspirone is a prescription medication. Ask your doctor if Buspirone is right for you.
Other strengths and forms of Buspirone
Conditions Treated with Buspirone
- Anxiety
- Anxiety Disorder
- Generalized Anxiety Disorder
- Generalized Anxiety Disorder / Panic Disorder
- Panic disorder
How to Check Buspirone Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Buspirone at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Anxiety
Also listed for Anxiety Disorder
Also listed for Generalized Anxiety Disorder
Other medications in Mental Health
What Buspirone is approved for (FDA label)
Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months.
Source: Read the full FDA label on DailyMed. Label effective date: May 15, 2024.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Buspirone (FDA label)
(See also PRECAUTIONS .) Commonly Observed The more commonly observed untoward events associated with the use of buspirone hydrochloride tablets not seen at an equivalent incidence among placebo-treated patients include dizziness, nausea, headache, nervousness, lightheadedness, and excitement. Associated with Discontinuation of Treatment One guide to the relative clinical importance of adverse events associated with buspirone hydrochloride tablets is provided by the frequency with which they caused drug discontinuation during clinical testing. Approximately 10% of the 2200 anxious patients who participated in the buspirone hydrochloride tablets premarketing clinical efficacy trials in anxiety disorders lasting 3 to 4 weeks discontinued treatment due to an adverse event.
Source: FDA prescribing information (DailyMed). Set ID: 18e90d65-4a3a-864e-e063-6294a90ae99d. SPL document ID: 18e9092c-7992-80e0-e063-6294a90a73fb. Label effective date: May 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Buspirone (FDA label)
Buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. The use of buspirone within 14 days of stopping an MAOI intended to treat depression is also contraindicated. Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS , DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS ).
Source: FDA prescribing information (DailyMed). Set ID: 18e90d65-4a3a-864e-e063-6294a90ae99d. SPL document ID: 18e9092c-7992-80e0-e063-6294a90a73fb. Label effective date: May 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Buspirone (FDA label)
Psychotropic Agents MAO inhibitors The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. The use of buspirone within 14 days of stopping an MAOI intended to treat depression is also contraindicated. Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS , DOSAGE AND ADMINISTRATION AND CONCOMITANT DRUG ). Amitriptyline After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (C max , AUC, and C min ) of amitriptyline or its metabolite nortriptyline were observed.
Source: FDA prescribing information (DailyMed). Set ID: 18e90d65-4a3a-864e-e063-6294a90ae99d. SPL document ID: 18e9092c-7992-80e0-e063-6294a90a73fb. Label effective date: May 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.